Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis.

Abstract A meta-analysis was conducted of individual patient data ( n = 3292) from three randomized controlled trials of corifollitropin alfaversus rFSH: Engage (150 µg corifollitropin alfan = 756; 200 IU rFSH n = 750), Ensure (100 µg corifollitropin alfan = 268; 150 IU rFSH n = 128), and Pursue (150 µg corifollitropin alfan = 694; 300 IU rFSH n = 696). Women with regular menstrual cycles aged 18–36 and body weight >60 kg (Engage) or ≤60 kg (Ensure), or women aged 35–42 years and body weight ≥50 kg (Pursue), received a single injection (100 µg or 150 µg) of corifollitropin alfa(based on body weightand age) or daily rFSH. The difference ( corifollitropin alfaminus rFSH) in the number of oocytes retrieved was +1.0 (95% CI: 0.5–1.5); vital pregnancy rate: −2.2% (95% CI: −5.3%–0.9%); ongoing pregnancy rate: −1.7% (95% CI: −4.7%–1.4%); and live birth rate: −2.0% (95% CI: −5.0%–1.1%). The odds ratio for overall OHSS was 1.15 (95% CI: 0.82–1.61), and for moderate-to-severe OHSS: 1.29 (95% CI: 0.81–2.05). A single dose of corifollitropin alfafor the first 7 days of ovarian stimulation is a generally well-tolerated and similarly effective treatment compared with daily rFSH.